Baekeland Fonds Home Baekeland Fonds I Baekeland Fonds II English Nederlands
Successful TiGenix IPO prompts early closing PDF

TiGenix raises EUR 40 million at EUR 5.00 per share
IPO 4.5 times oversubscribed

Leuven (BELGIUM) – March 21, 2007 - TiGenix, the biomedical company focused on innovative local treatments for damaged and osteoarthritic joints, today confirms an early closing of the public offer to subscribe to its capital increase. Pursuant to the offering, 8,000,000 new shares will be issued by TiGenix equivalent to EUR 40 million. The final offering price amounts to EUR 5.00 per share. Shares will start trading as of 22 March 2007 on the Eurolist by Euronext Brussels under the symbol TIG.

Details of the Offering

  • The proceeds for TiGenix raised through the offering amount to EUR 40 million at EUR 5.00 per share. If the over-allotment option is fully exercised, the total amount can increase to EUR 46 million.
  • The total offering was oversubscribed 4.5 times. The part of the offering reserved for retail investors was oversubscribed more than 5 times. The part of the offering reserved for institutional investors was oversubscribed more than 4 times.
  • The retail investors in Belgium are allocated 1,200,000 shares, representing 15% of the capital increase.
  • The listing and trading of the shares are to commence on March 22, 2007 on an “asif- and-when-issued” basis, under the symbol TIG.
  • The payment of the shares and the completion of the capital increase will take place on March 27, 2007.
  • The lead managers are granted an over-allotment option to subscribe to 1,200,000 additional shares at a price of EUR 5.00 per share. The option is exercisable as of listing until 30 days following the closing date of the offering. All shares covered by the over-allotment option are new shares.
Shares requestedApplications submitted with ING, Petercam & Piper JaffrayApplications submitted with other financial intermediaries
1-503015
51-1005025
101-2507538
251-50015075
501-1 000275138
1 001-5 000500250
As from 5 0011 000500

Gil Beyen, co-founder and CEO of TiGenix, comments on the successful closing of the IPO: “We are extremely pleased with the success of this offering, both with retail and institutional investors as well as with the quality of the institutional investors who have participated in the offering. We look forward to our listing and would like to thank our people and shareholders for their hard work and support.”

For more information, please contact

Gil Beyen
Chief Executive Officer
+32 16 39 60 60
Kris Motmans
representative of MC-Services Group Corporate Communications
+32 16 39 60 63